Elironrasib

Overview

Elironrasib is an orally active and covalent inhibitor of KRAS G12C (ON) . Elironrasib forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA). Thus, Elironrasib prevents KRAS G12C (ON) from signaling via steric blockade of RAS effector binding. Elironrasib inhibits ERK signaling and induced apoptosis in KRASG12C-mutant H358 cells. Elironrasib also inhibits the proliferation of KRAS G12C mutant cells with a median IC 50 of 0.11 nM.

Application

Products | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > Ras | Products > Signaling Pathways > ERK | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-153346
• CAS No.: 2641998-63-0
• Molecular Formula: C55H78FN9O8
• Molecular Weight: 1012.26
• Purity: 99.42%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (2.47 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source